# Merck sees pivotal victory for $3B eye disease prospect

> **Open Intelligence Dossier** · First detected: 2026-09-25 01:00 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Merck sees pivotal victory for $3B eye disease prospect" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Ophthalmology Times, Business Wire, Endpoints News and Reuters. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Ophthalmology Times | Remigromig noninferior to ranibizumab in phase 2b/3 BRUNELLO DME trial - Eye Care Network - Modern Retina | [Source Link](https://news.google.com/rss/articles/CBMipwFBVV95cUxPNjI5aDJLWV8xWTk3eXRpVThha0lsYUwzLUxMVHVSYk14RkcteHQ2U2R6eVZ5NkJDb1VFRU5tT3NaVDhVQ2M5ckNObTlwcEtXbm1xTTJ0YnI1MFE5enpMdThKQ2djTkRFUk5wc1Zma1cyUkFjSHpyNVdKS3RXTmE2MFc3aGowTUZ6clJzSGRCZFI2ajlKZFNZVzFfWE80eVU5VzJydXYzQQ?oc=5) |
| Business Wire | Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema | [Source Link](https://news.google.com/rss/articles/CBMi6AJBVV95cUxNRFZISlVucDdYUXBVaWRTXzRuNE1xWC1WUEwwNzB0ZTZNQjM0ZkZQOUlYQkk4a3A1N2VleW1FZFQ2eXVYQ0pTS3N6NDI2N3ZzbnRMU3FYb1VQOGhfcTBFaTlhNWpxRzJ5VC1yOXFLWDdnVFhGeE50T0t4aDJRQkxKX3M2UlZHSnQ3ZW52YmIzY3NOQmp3cExkVGNYNjFYMU1QTzJ1Z0Rscm9aRHVMV0tOY09sbkRhZndRSGhUbU1hbGJYOGVXNGNpSG1RSmFsVWY0YTZsZXZmdFVaOUVnOHAtNFBuSEx4dW85OE9qaTdrVklCU0hEaDhHcVF2X1Y2N1F6RTJtbHRTMURVbFlzNXZDdlI4WnMtYVhRVXFyVWY5dFVhZzRWc2NFRXZoV01uRkw5bzNzREJFNFRzUWhzWEFQSFdwcGVyMDM5dUVLdXVpZzhsLUd1OVd) |
| Endpoints News | Merck’s return to ophthalmology snags first success | [Source Link](https://news.google.com/rss/articles/CBMif0FVX3lxTE9lZEpFQk5jNC01RTUyS0xVY1BHeHFtYk93RVg2LWFFVndFQjJCZGZCNzBLUGlCWUhfcWRUYllnLTAtTWsxZmIzX0FzVU1KVWQzX3FoNS1WeDNnTmpPbXktXzRfMkZvdGw2VkJNVWVPeUxMcHFVUjNvc09BSU93cWs?oc=5) |
| Reuters | Merck's drug for diabetes-related eye disease meets trial goal | [Source Link](https://news.google.com/rss/articles/CBMiuAFBVV95cUxQd3JwRm1OSGhUUHQ2V3dvRlBYbGVXb2kzQjBWa2tqbF9STlZXYUpWVmVZa1FFQmI4V0VlbEZDbmp2NUVDdkQtYmUzODBWYTZ2Z01fdF9Zb3NiaDlFU0F3ZVVkMV9scnVOcGdJS2c3bUpfT1JhRUlyNE5LQnNxLXJHMDlab2ZYampFNk1EdjZPVk93dTFEX25mZFF1QThzMUFXc3BjZV90UzEyZjNpWktxTzVraC05dXN6?oc=5) |
| Fierce Biotech | Merck sees pivotal victory for $3B eye disease prospect | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxNdFBLeUMxU0s4M2hxLTNGY2VNbjdObWZiU0JfUmRERUhNUzU5NUVMZWNNN2hPV2UwUk9WdkJIYU50NUZUdW4xWjdhaU81LURIN2lRTW1EdkhTMHc1MFNydFpMWGZTSWI1bGRoeHAtdnRzZlJrMUFkZmhxMGQzczNHWDhQVUFhU1phLTA2MWduOTBFNE9RTWJkdDJR?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-25/merck-sees-pivotal-victory-for-3b-eye-disease-prospect*